Finanzen von Beam Therapeutics Inc. (BEAM)BEAMBeam Therapeutics Inc.

Evaluating the bottom line, Beam Therapeutics Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -25827.14%, while the net margin is -25036.33%. These profitability ratios, combined with a Return on Equity (ROE) of -8.18%, provide a clear picture of how effectively BEAM converts its operational activities into shareholder value.

In the context of the broader market, BEAM competes directly with industry leaders such as MBX and CLDX. With a market capitalization of $2.76B, it holds a significant position in the sector. When comparing efficiency, BEAM's gross margin of 100.00% stands against MBX's N/A and CLDX's 100.00%. Such benchmarking helps identify whether Beam Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

Beam Therapeutics has shown a substantial increase in total revenue, with Q4 2025 revenue reported at $114.11 million, a significant jump from previous quarters. The gross margin remains strong at 100%, indicating efficient cost management despite the ongoing losses.